Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study

Autor: Mego, M., Huddart, R. A., Voortman, J., Ong, M., Gedye, C., Gurney, H., Fay, A. P., Bamias, A., Mellado Gonzalez, B., Loriot, Y., Merseburger, A. S., Castellano Gauna, D., de Ducla, S., Pavlova, J., Fear, S., Sternberg, C. N.

Publikováno v: Annals of Oncology, 31, S591-S591. Oxford University Press
Mego, M, Huddart, R A, Voortman, J, Ong, M, Gedye, C, Gurney, H, Fay, A P, Bamias, A, Mellado Gonzalez, B, Loriot, Y, Merseburger, A S, Castellano Gauna, D, de Ducla, S, Pavlova, J, Fear, S & Sternberg, C N 2020, ' Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study ', Annals of Oncology, vol. 31, pp. S591-S591 . https://doi.org/10.1016/j.annonc.2020.08.838

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::24d6545c8ec7c5acc66ba6e2ec8909b4
https://research.vumc.nl/en/publications/87c55a6e-4faf-48ed-aea2-27cb08420fe9

Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract

Autor: Sternberg, C.N. Loriot, Y. James, N. Choy, E. Castellano, D. Lopez-Rios, F. Banna, G.L. De Giorgi, U. Masini, C. Bamias, A. Garcia del Muro, X. Duran, I. Powles, T. Gamulin, M. Zengerling, F. Geczi, L. Gedye, C. de Ducla, S. Fear, S. Merseburger, A.S.

Background: Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a broader, pretreated population, including patients ineligible for the pivota

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::38a5c318e70aba4237a50a6f72e251a8
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3105899

927P - Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)

Autor: Hoffman-Censits, J., Rosenberg, J.E., van Der Heijden, M., Dreicer, R., Perez Gracia, J.L., Petrylak, D.P., Retz, M.M., Sabbatini, R., Naglieri, E., Caserta, C., Maruzzo, M., Iacovelli, R., Galli, L., McDermott, R., Morales Barrera, R., Bonfill, T., De Ducla, S., Ding, B., Linsenmeier, J., Sternberg, C.N.

Publikováno v: In Annals of Oncology October 2019 30 Supplement 5:v372-v373

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

1542P - Exploratory analyses of candidate predictive and prognostic tissue biomarkers (BMs) in the open-label randomised phase III TANIA trial of bevacizumab (BEV) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

Autor: Zielinski, C., Gligorov, J., Marschner, N., Puglisi, F., Vrdoljak, E., Castan, J. Cortes, de Ducla, S., Deurloo, R., Easton, V., von Minckwitz, G.

Publikováno v: In Annals of Oncology 1 October 2016 27 Supplement 6:vi533-vi533